SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-24-094630
Filing Date
2024-11-05
Accepted
2024-11-05 17:10:15
Documents
1
Period of Report
2024-11-01

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1539
  Complete submission text file 0001213900-24-094630.txt   3086
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address
Almenoff June Sherie (Reporting) CIK: 0001492647 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36374 | Film No.: 241428487